Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Salary and Exercises Stock Options
SEC Form 4
A Form 4 filing reveals Agenus Inc. CEO Garo H. Armen received stock in lieu of cash salary and exercised stock options.
Summary
- A Form 4 filing details changes in beneficial ownership for Garo H. Armen, CEO of Agenus Inc.
- Armen received 1,055 shares of common stock on June 14, 2024, as payment for his salary, valued at $15.46 per share.
- He also acquired 65,651 and 108,000 stock options on June 11, 2024, with an exercise price of $11.9, vesting at different schedules.
- The filing also indicates Armen indirectly owns 31,298 shares through IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.
- The stock options were granted on January 17, 2024, subject to shareholder approval obtained on June 11, 2024, and were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.
- The stock options were granted prior to the 1 for 20 reverse stock split, representing 1,313,020 and 2,160,000 Stock Options with an exercise price of $0.59.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The CEO taking stock in lieu of salary could be seen as a slightly positive signal.
Positives
- The CEO's acceptance of stock in lieu of salary demonstrates confidence in the company's future.
- The granting and exercising of stock options aligns management's interests with those of shareholders.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- Shareholders may view the CEO's stock transactions as a reflection of their confidence in the company.
- Employees may be impacted by the overall performance of the company, which is indirectly linked to executive incentives.
Key Dates
| Date | Description |
|---|---|
| 01/17/2024 | Date stock options were granted, subject to shareholder approval. |
| 06/11/2024 | Date of Agenus Inc.'s annual shareholder meeting where shareholder approval for the stock options was obtained. |
| 06/11/2024 | Date Garo H. Armen acquired 65,651 and 108,000 stock options. |
| 06/14/2024 | Date Garo H. Armen received 1,055 shares of common stock as salary payment. |
| 06/18/2024 | Date of the Form 4 filing. |
| 01/17/2034 | Expiration date for 65,651 stock options. |
| 01/11/2034 | Expiration date for 108,000 stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.